HLB Liver Cancer Drug Application Accepted by FDA Business & Economy HLB Liver Cancer Drug Application Accepted by FDA editor 7월 15, 2026 HLB’s Rivoceranib Gains Momentum as FDA Issues VAI for China Production Site, Boosting Shares HLB’s corporate logo...Read More
